Search Result

Results for "

IRAK4 degrader

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AAK1 (1) Apoptosis (9) Autophagy (2) CDK (1) E3 Ligase Ligand-Linker Conjugates (1) Ephrin Receptor (1) FGFR (1) IFNAR (1) Interleukin Related (1) IRAK (22) Itk (1) Ligands for E3 Ligase (3) Ligands for Target Protein for PROTAC (2) MAP4K (1) MELK (1) NF-κB (2) p38 MAPK (1) PROTAC Linkers (2) PROTACs (21) TNF Receptor (1) ULK (1) Wee1 (1)
By Research Areas:	Cancer (29) Inflammation/Immunology (5)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-129966

*PROTAC IRAK4* degrader-1** 1 Publications Verification	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-1 (compound I-210) is a Cereblon-based IRAK4 PROTAC. PROTAC IRAK4 degrader-1 is composed of IRAK4 ligand (red part) PROTAC IRAK4 ligand-1 (HY-129967), E3 ligase ligand (blue part) Pomalidomide (HY-10984), and PROTAC linker (black part) AM-Imidazole-PA-Boc (HY-129968) .

HY-135382A

*PROTAC IRAK4* degrader-3**	IRAK PROTACs	Inflammation/Immunology
PROTAC IRAK4 degrader-3 is a PROTAC-induced *IRAK4* degrader based on von Hippel-Lindau .

HY-135382

*PROTAC IRAK4* degrader-2**	PROTACs IRAK	Inflammation/Immunology Cancer
PROTAC IRAK4 degrader-2 (Compound 9) is a PROTAC-based IRAK4 degrader that affords potent IRAK4 degradation with a DC₅₀ in peripheral blood mononuclear cells (PBMCs) cells of 151 nM. PROTAC IRAK4 degrader-2 induce a reduction of IRAK4 protein levels with a DC₅₀ of 36 nM in PBMC cells. PROTAC IRAK4 degrader-2 also leads to the inhibition of multiple cytokines in PBMCs .

HY-168586

*PROTAC IRAK4* degrader-12**	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-12 is a PROTAC based on Cereblon ligand, inducing a maximum degradation rate of IRAK4 of 108.46% in K562 cells with an IC₅₀ value of 4.87 nM ( Structure Note: Pink, IRAK4 inhibitor (HY-168611); Blue, E3 (HY-W733885); Black, linker (HY-168613)) .

HY-153673

*PROTAC IRAK4* degrader-8**	IRAK PROTACs	Cancer
PROTAC IRAK4 degrader-8 (Compound 2) is a PROTAC *IRAK4* degrader (IC₅₀: 15.5 nM). PROTAC IRAK4 degrader-8 degrades IRAK4 in THP-1 cells (DC₅₀: 1.8 nM)。PROTAC IRAK4 degrader-8 also inhibits L-6 production in human whole blood and LPS-induced human PBMC cells, with IC₅₀s of 246 nM and 2.2 nM respectively .

HY-139316

*PROTAC IRAK4* degrader-5**	IRAK PROTACs	Cancer
PROTAC IRAK4 degrader-5 is a Cereblon-based *IRAK4* degrader extracted from patent US20190192668A1, compound I-171 .

HY-158758

*PROTAC IRAK4* degrader-10**	PROTACs IRAK	Inflammation/Immunology
PROTAC IRAK4 degrader-10 (compound 10) is an oral active PROTAC based on Cereblon ligand, and induces the degradation of IRAK4 with maximum degradation of 95.94% and the DC₅₀ of 7.68 nM in HEK293 cells (Sturcture Note:(Blue: Cereblon ligand, Black: linker；Pink: IRAK4 ligand) .

HY-158760

*PROTAC IRAK4* degrader-11**	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-11 (compound 15) is PROTAC based on Cereblon ligand, and induces the degradation of IRAK4 with maximum degradation of 96.25% and the DC₅₀ of 2.29 nM in HEK293 cells(Sturcture Note:(Blue: Cereblon ligand (HY-14658), Black: linker；Pink: IRAK4 inhibitor) .

HY-139315

*PROTAC IRAK4* degrader-4**	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-4 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-127 .

HY-139317

*PROTAC IRAK4* degrader-6**	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-6 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-172 .

HY-145483

KT-474 KYM-001; PROTAC IRAK4 degrader-7	PROTACs IRAK Apoptosis	Cancer
KT-474 (KYM-001) is an orally active PROTAC IRAK4 degrader with antitumor activities . KT-474 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-148276

KTX-497	PROTACs IRAK	Cancer
KTX-497 is an *IRAK4* PROTAC degrader with a DC₅₀ value of 3 nM. KTX-497 can be used for the research of oncology ^[1].(Pink:IRAK4 inhibitor (HY-150735); Black: linker; Blue: CRBN Ligand (HY-10984))

HY-148277

KTX-612	PROTACs IRAK	Cancer
KTX-612 is an orally active *IRAK4* PROTAC degrader with a DC₅₀ value of 7 nM. KTX-612 can be used for the research of oncology ^[1].(Pink:IRAK4 inhibitor (HY-150735); Black: linker; Blue: CRBN Ligand (HY-10984))

HY-129967

PROTAC IRAK4 ligand-1	Ligands for Target Protein for PROTAC	Cancer
PROTAC IRAK4 ligand-1 is a synthetic ligand for interleukin-1 receptor-associated kinase 4 (IRAK4). PROTAC IRAK4 ligand-1 can be used in the synthesis of PROTAC IRAK4 degrader-1 (HY-129966) .

HY-168611

PROTAC IRAK4 ligand-4	Ligands for Target Protein for PROTAC IRAK	Cancer
PROTAC IRAK4 ligand-4 is a Ligand for Target Protein for PROTAC with antitumor activity. PROTAC IRAK4 ligand-4 can be used to synthesize PROTAC IRAK4 degrader-12 (HY-168586) .

HY-W087383

Thalidomide 5-fluoride	Ligands for E3 Ligase Autophagy Apoptosis	Cancer
Thalidomide 5-fluoride is a thalidomide-based Cereblon ligand used to recruit Cereblon protein. Thalidomide 5-fluoride can be linked to target protein ligands (e.g. *IRAK4) through a linker to form PROTAC molecules (e.g. PROTAC IRAK4* degrader-1). PROTAC IRAK4 degrader-1 caused <20%, >20-50%, and >50% IRAK4 protein degradation in OCI-LY-10 cells at concentrations of 0.01, 0.1, and 1 μM, respectively .

HY-148275

KTX-955	PROTACs IRAK	Cancer
KTX-955 is an antumor and effective *IRAK4* degrader, with DC₅₀ values of 5 nM and 130 nM for IRAK4 and Ikaros, respectively . KTX-955 is composed of CRBN ligand (blue part) Pomalidomide (HY-10984) and target protein ligand (red part) IRAK4-IN-20 (HY-150735).

HY-41547

Thalidomide 4-fluoride Cereblon ligand 4; E3 ligase Ligand 4	Ligands for E3 Ligase Autophagy Apoptosis	Cancer
Thalidomide 4-fluoride (Cereblon ligand 4) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide 4-fluoride (Cereblon ligand 4) can be connected to the ligand for IRAK4 protein by a linker to form PROTAC IRAK4 degrader-1 (HY-129966) .

HY-49435

KTX-582 intermediate-3	Apoptosis	Cancer
KTX-582 intermediate-3 is an intermediate in the synthesis of KTX-582 (HY-148274) and can be used for ADC preparation. KTX-582 is an IRAK4 degrader and inducer of apoptosis with DC₅₀ of 4 nM and 5 nM for IRAK4 and Ikaros, respectively .

HY-49436

KTX-582 intermediate-1	Apoptosis	Cancer
KTX-582 intermediate-1 is an intermediate in the synthesis of KTX-582 (HY-148274) and can be used for ADC preparation. KTX-582 is an IRAK4 degrader and inducer of apoptosis with DC_{50_{of 4 nM and 5 nM for IRAK4 and Ikaros, respectively ^{[1] ^.}}}

HY-49432

KTX-582 intermediate-2	Apoptosis	Cancer
KTX-582 intermediate-2 is an intermediate in the synthesis of KTX-582 (HY-148274) and can be used for ADC preparation. KTX-582 is an IRAK4 degrader and inducer of apoptosis with DC_{50_{of 4 nM and 5 nM for IRAK4 and Ikaros, respectively ^{[1] ^.}}}

HY-148274

KTX-582	PROTACs IRAK Apoptosis	Cancer
KTX-582 is a potent *IRAK4* degrader with DC₅₀ values of 4 nM and 5 nM for IRAK4 and Ikaros, respectively. KTX-582 can induce apoptosis in MYD88 ^MT DLBCL, and is efficient to induce in vivo tumor regressions in lymphoma model .

HY-172590

LZ-07	PROTACs IRAK Interleukin Related TNF Receptor	Inflammation/Immunology
LZ-07 is a IRAK4 PROTAC degrader (DC₅₀ = 1.14 nM). LZ-07 leads to marked suppression of cytokines including IL-6, IL-1β, TNF-α, and IL-10 upon degradation of IRAK4. LZ-07 can be studied in research for autoimmune diseases (Pink: IRAK4 ligand (HY-172591); Blue: CRBN ligand (HY-34590); Black: linker (HY-B0149); CRBN ligand + linker: HY-172593) .

HY-129968

AM-Imidazole-PA-Boc	PROTAC Linkers	Cancer
AM-Imidazole-PA-Boc is an alkyl chain-based PROTAC linker can be used in the synthesis of PROTAC IRAK4 degrader-1 (HY-129966) .

HY-148290

KTX-951	PROTACs IRAK	Cancer
KTX-951 is an orally active *IRAK4* and IMiD (Ikaros/Aiolos) substrates PROTAC degrader (K_d = 3.5 nM). KTX-951 has DC₅₀s of 13 nM, 14 nM and 13 nM for IRAK4, Ikaros and Aiolos, respectively. KTX-951 has IC₅₀ of 35 nM for OCl-Ly10 CTG. KTX-951 has antitumor activity.(Pink: IRAK4 ligand-12 (HY-48932); Black: Linker (HY-W382009); Blue: CRBN Ligand Pomalidomide (HY-10984)) .

HY-W733885

E3 ligase Ligand 38	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 38 serves as the E3 ligase ligand for PROTAC IRAK4 degrader-12 (HY-168586) and can be used in the synthesis of PROTACs.

HY-168612

E3 Ligase Ligand-linker Conjugate 125	E3 Ligase Ligand-Linker Conjugates	Cancer
E3 Ligase Ligand-linker Conjugate 125 is an E3 ligase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 125 can be used to synthesize PROTAC IRAK4 degrader-12 (HY-168586) .

HY-75005

1-Boc-4-carboxymethyl piperazine	PROTAC Linkers	Cancer
1-Boc-4-carboxymethyl piperazine is a PROTAC linker. 1-Boc-4-carboxymethyl piperazine can be used in the synthesis of PROTACs (e.g. PROTAC IRAK4 degrader-12 (HY-168586)) .

HY-153368

Zomiradomide KT-413	PROTACs IRAK NF-κB IFNAR	Cancer
Zomiradomide is an orally active PROTAC degrader for *IRAK4* (DC₅₀=6 nM), thereby inhibiting the NF-κB signaling pathway. Zomiradomide acts also as a molecular glue, recruiting Ikaros and Aiolos, and mediating their degradation (DC₅₀ for Ikaros is 1 nM), thereby activating the type I IFN signaling pathway . (Pink: target protein ligand PROTAC IRAK4 ligand-5 (HY-168311), Blue: E3 ligase ligand Thalidomide-4-Br (HY-W039116), Black: linker (HY-168313))

HY-162538

LC-MI-3	NF-κB IRAK PROTACs	Inflammation/Immunology
LC-MI-3 is an orally active and potent interleukin-1 receptor-associated kinase 4 (IRAK4) PROTAC degrader, with a DC₅₀ of 47.3 nM. LC-MI-3 effectively inhibits the activation of downstream NF-κB signaling. LC-MI-3 can be used for the research of acute and chronic inflammatory skin. (Blue: VHL ligand, Black: linker, Pink: CRBN ligand (HY-14658)) .

HY-W093067

KTX-582 intermediate-4	Apoptosis	Cancer
KTX-582 intermediate-4 (intermediate 2-1)is a synthesis IRAK4Degrading agent KTX-582 (HY-148274)of intermediates. KTX-582It is also an effective form of apoptosis (apoptosis)inducer .

HY-153188

JNJ-1013	PROTACs Apoptosis IRAK	Cancer
JNJ-1013 is a potent and selective IRAK1 PROTAC degrader with an IC₅₀s of 72, 443, 1071 nM for IRAK1, IRAK4, VHL FP respectively. JNJ-1013 induces apoptosis and increases the expression of cleavaged PARP. JNJ-1013 decreases the expression IRAK1, p-IKBα, pSTAT3(Tyr705) (Pink: ligand for target protein (HY-138834); black: linker (HY-Y1760); Blue: E3 ligase ligand (HY-112078)) .

HY-148065

FMF-06-098-1	PROTACs Wee1 CDK AAK1 ULK MELK Itk IRAK Ephrin Receptor FGFR MAP4K p38 MAPK	Cancer
FMF-06-098-1 is a multi-target kinase PROTAC degrader. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 (Pink: target protein ligand (HY-169396); Blue: VHL ligand (HY-112078); Black: Linker (HY-124380)) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

IRAK4 degrader

Inhibitors & Agonists